Literature DB >> 26420071

HIV transmission law in the age of treatment-as-prevention.

Bridget Haire1, John Kaldor1.   

Abstract

Evidence that treating people with HIV early in infection prevents transmission to sexual partners has reframed HIV prevention paradigms. The resulting emphasis on HIV testing as part of prevention strategies has rekindled the debate as to whether laws that criminalise HIV transmission are counterproductive to the human rights-based public health response. It also raises normative questions about what constitutes 'safe(r) sex' if a person with HIV has undetectable viral load, which has significant implications for sexual practice and health promotion. This paper discusses a recent high-profile Australian case where HIV transmission or exposure has been prosecuted, and considers how the interpretation of law in these instances impacts on HIV prevention paradigms. In addition, we consider the implications of an evolving medical understanding of HIV transmission, and particularly the ability to determine infectiousness through viral load tests, for laws that relate to HIV exposure (as distinct from transmission) offences. We conclude that defensible laws must relate to appreciable risk. Given the evidence that the transmissibility of HIV is reduced to negligible level where viral load is suppressed, this needs to be recognised in the framing, implementation and enforcement of the law. In addition, normative concepts of 'safe(r) sex' need to be expanded to include sex that is 'protected' by means of the positive person being virally suppressed. In jurisdictions where use of a condom has previously mitigated the duty of the person with HIV to disclose to a partner, this might logically also apply to sex that is 'protected' by undetectable viral load. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Criminal Law; HIV Infection and AIDS; Law; Public Health Ethics

Mesh:

Substances:

Year:  2015        PMID: 26420071     DOI: 10.1136/medethics-2014-102122

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  "We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.

Authors:  Karine Dubé; David Evans; Lynda Dee; Laurie Sylla; Jeff Taylor; Asheley Skinner; Bryan J Weiner; Sandra B Greene; Stuart Rennie; Joseph D Tucker
Journal:  AIDS Res Hum Retroviruses       Date:  2017-07-10       Impact factor: 2.205

2.  Awareness and understanding of HIV non-disclosure case law among people living with HIV who use illicit drugs in a Canadian setting.

Authors:  Sophie Patterson; Angela Kaida; Gina Ogilvie; Robert Hogg; Valerie Nicholson; Sabina Dobrer; Thomas Kerr; Jean Shoveller; Julio Montaner; M-J Milloy
Journal:  Int J Drug Policy       Date:  2017-03-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.